James D. McKay

2.4k total citations · 1 hit paper
13 papers, 1.7k citations indexed

About

James D. McKay is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, James D. McKay has authored 13 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Rheumatology, 7 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Immunology. Recurrent topics in James D. McKay's work include Systemic Lupus Erythematosus Research (9 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and T-cell and B-cell Immunology (4 papers). James D. McKay is often cited by papers focused on Systemic Lupus Erythematosus Research (9 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and T-cell and B-cell Immunology (4 papers). James D. McKay collaborates with scholars based in United States, United Kingdom and Spain. James D. McKay's co-authors include Mark C. Genovese, Eduardo Mysler, Е. Л. Насонов, Thasia Woodworth, Emma Alecock, Nilzio A Da Silva, Juan J. Gómez‐Reino, Richard Furie, Joan T. Merrill and William Stohl and has published in prestigious journals such as Annals of the Rheumatic Diseases, British Journal of Clinical Pharmacology and Arthritis & Rheumatology.

In The Last Decade

James D. McKay

13 papers receiving 1.6k citations

Hit Papers

Interleukin‐6 receptor inhibition with tocilizumab reduce... 2008 2026 2014 2020 2008 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study
    2008 655 citations Mark C. Genovese, James D. McKay et al. Arthritis & Rheumatism profile →

Peers

James D. McKay
Renato Guzmán United States
Asad Zoma United Kingdom
Joseph C. Shanahan United States
Piotr Leszczyński Poland
Joy Schechtman United States
M. L. Snaith United Kingdom
T. Li United States
David Musselman United States
Lee Suan Teh United Kingdom
Jennifer M. Grossman United States
Renato Guzmán United States
James D. McKay
Citations per year, relative to James D. McKay James D. McKay (= 1×) peers Renato Guzmán

Countries citing papers authored by James D. McKay

Since Specialization
Citations

This map shows the geographic impact of James D. McKay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James D. McKay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James D. McKay more than expected).

Fields of papers citing papers by James D. McKay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James D. McKay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James D. McKay. The network helps show where James D. McKay may publish in the future.

Co-authorship network of co-authors of James D. McKay

This figure shows the co-authorship network connecting the top 25 collaborators of James D. McKay. A scholar is included among the top collaborators of James D. McKay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James D. McKay. James D. McKay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Wallace, Daniel J., Ellen M. Ginzler, Joan T. Merrill, et al.. (2019). Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology. 71(7). 1125–1134. 84 indexed citations
2.
Wallace, DJ, EM Ginzler, JT Merrill, et al.. (2017). OP0232 Sustained safety and efficacy over 10 years with belimumab (BEL) plus standard systemic lupus erythematosus (SLE) therapy (SOC) in patients with SLE. Annals of the Rheumatic Diseases. 76. 150–151. 5 indexed citations
3.
Stohl, William, Joan T. Merrill, James D. McKay, et al.. (2013). Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study. The Journal of Rheumatology. 40(5). 579–589. 77 indexed citations
4.
Ginzler, Ellen M., Daniel J. Wallace, Joan T. Merrill, et al.. (2013). Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus. The Journal of Rheumatology. 41(2). 300–309. 130 indexed citations
5.
Merrill, Joan T., Ellen M. Ginzler, Daniel J. Wallace, et al.. (2012). Long‐term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis & Rheumatism. 64(10). 3364–3373. 88 indexed citations
6.
Chatham, Winn, Daniel J. Wallace, William Stohl, et al.. (2012). Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial. The Journal of Rheumatology. 39(8). 1632–1640. 66 indexed citations
7.
Wallace, Daniel J., William Stohl, Richard Furie, et al.. (2009). A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Care & Research. 61(9). 1168–1178. 408 indexed citations
8.
Genovese, Mark C., James D. McKay, Е. Л. Насонов, et al.. (2008). Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study. Arthritis & Rheumatism. 58(10). 2968–2980. 655 indexed citations breakdown →
9.
Alarcón-Segovia, D, James A. Tumlin, Richard Furie, et al.. (2003). LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double‐blind, placebo‐controlled study. Arthritis & Rheumatism. 48(2). 442–454. 183 indexed citations
10.
Bridges, Alan J., James D. Anderson, James D. McKay, et al.. (1993). Antinuclear Antibody Testing in a Referral Laboratory. Laboratory Medicine. 24(6). 345–349. 7 indexed citations
11.
McKay, James D., et al.. (1988). The use of lithium clearance measurements to assess renal tubular function in experimental and clinical cyclosporine nephrotoxicity.. Transplantation Proceedings. 20(3 Suppl 3). 675–80. 7 indexed citations
12.
McKay, James D., et al.. (1982). The acute effects of ethanol on acetanilide disposition in normal subjects, and in patients with liver disease.. British Journal of Clinical Pharmacology. 14(4). 501–504. 3 indexed citations
13.
Wilson, Ian C., James D. McKay, & Myron G. Sandifer. (1961). A Double-Blind Trial to Investigate the Effects of Thorazine (Largactil, Chlorpromazine), Compazine (Stemetil, Prochlorperazine) and Stelazine (Trifluoperazine) in Paranoid Schizophrenia. Journal of Mental Science. 107(446). 90–99. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Renato Guzmán Breakdown of academic impact, for papers by Asad Zoma Breakdown of academic impact, for papers by Joseph C. Shanahan Breakdown of academic impact, for papers by Piotr Leszczyński Breakdown of academic impact, for papers by Joy Schechtman Breakdown of academic impact, for papers by M. L. Snaith Breakdown of academic impact, for papers by T. Li Breakdown of academic impact, for papers by David Musselman Breakdown of academic impact, for papers by Lee Suan Teh Breakdown of academic impact, for papers by Jennifer M. Grossman
Rankless by CCL
2026